IKT — Inhibikase Therapeutics Inc · $215.2M cap

Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.

Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.

Use this IKT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IKT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IKT SEC filings page. Lician reads the product cache first so this HTML stays unique to Inhibikase Therapeutics Inc even when a live quote feed is slow.

Inhibikase Therapeutics Inc latest statements (FY2025)

Latest cached year on this hub. Full IKT income, balance, and cash tables.

  • Revenue$0
  • Net Income-$48.3M
  • Total Assets$181.2M
  • Total Debt$0
  • Free Cash Flow-$27.8M

IKT recent filings